‘Real world’ use of non-vitamin K antagonist oral anticoagulants (NOACS): Lessons from the dresden NOAC registry

Thrombosis and Haemostasis

Volumn 113, Issue 6, 2015, Pages 1159-1161

  Eikelboom, John W ^a   Weitz, Jeffrey I ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN; ANTITHROMBIN; DABIGATRAN;

ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DEATH; DISEASE ASSESSMENT; DISEASE REGISTRY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HAS BLED SCORE; HEART INFARCTION; HUMAN; MEDICATION COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCIENTIFIC LITERATURE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; FEMALE; ISCHEMIC ATTACK, TRANSIENT; MALE; STROKE;

ANTITHROMBINS; ATRIAL FIBRILLATION; DABIGATRAN; EMBOLISM; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; STROKE;

EID: 84931287757     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-02-0158     Document Type: Editorial

References (23)

1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.
2. Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 2014; 124: 1020–1028.
3. Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fi- brillation with the new oral anticoagulants. Thromb Haemost 2014; 111: 808–816.
4. Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost 2014; 111: 783–788.
5. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087–1107.
6. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in „real-world“patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264–2273.
7. Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. Br Med J Open 2013; 3.
8. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650–656.
9. Olesen JB, Sorensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013. Europace 2015; 17: 187–193.
10. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272–1274.
11. Vaughan Sarrazin MS, Jones M, et al. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014; 127: 1179–1185.
12. Hernandez I, Baik SH, Pinera A, et al. Risk of bleeding with dabigatran in atrial fibrillation. J Am Med Assoc Intern Med 2015; 175: 18–24.
13. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157–164.
14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
15. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry. Br J Clin Pharmacol 2014; 78: 908–917.
16. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35: 1888–1896.
17. Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955–962.
18. Chin PK, Wright DF, Patterson DM, et al. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol 2014; 78: 599–609.
19. Vanassche T, Hirsh J, Eikelboom JW, et al. Organspecific bleeding patterns of anticoagulated patient: lessons from clinical trials. Thromb Haemost 2014; 112: 918–923.
20. Chan NC, Coppens M, Hirsh J, et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost 2014; Epub ahead of print.
21. Camm AJ, Lip GY, DeCaterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719–2747.
22. Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 2014; 30: 1114–1130.
23. Beyer-Westendorf J, Ebertz F, Förster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113: 1247-1257.